Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: Application of film in situ zymography

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3290-3296

  Ikeda, Minoru ^a   Maekawa, Ryuji ^a   Tanaka, Hidekazu ^a   Matsumoto, Mitsunobu ^a   Takeda, Yukihiro ^a   Tamura, Yutaka ^b   Nemori, Ryoichi ^b   Yoshioka, Takayuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b FUJIFILM CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; GELATINASE A; MATRIX METALLOPROTEINASE INHIBITOR; N BIPHENYL SULFONYL PHENYLALANINE HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; ZYMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GELATIN; HUMANS; HYDROXAMIC ACIDS; KINETICS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033884067     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Liotta, L. A., and Stetler-Stevenson, W. G. Metalloproteinases and cancer invasion. Semin. Cancer Biol., 1: 99-106, 1990.
2. MacDougall, J. R., and Matrisian, L. M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev., 14: 351-362, 1995.
3. Jiang, W. G., Puntis, M. C. a., and Hallett, M. B. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br. J. Surg., 81: 1576-1590, 1994.
4. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
5. Bicknell, R., and Harris, A. L. Mechanisms and therapeutic implications of angiogenesis. Curr. Opin. Oncol., 8: 60-65, 1996.
6. Gastl, G., Hermann, T., Steurer, M., Zmija, J., Gunsilius, E., Unger, c., and Klaft, A. Angiogenesis as a target for tumor treatment. Oncology, 54: 177-184, 1997.
7. Mousa, S., A. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Future, 23: 51-60, 1998.
8. Winder, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
9. Yu, A. E., Herwitt, R. E., Connor, E. W., and Stetler-Stevenson, W. G. Matrix metalloproteinases: novel targets for directed cancer therapy. Drugs Aging, 11: 229-244, 1997.
10. Brown, P Matrix metalloproteinase inhibitors: a new class of anticancer agent. Curr. Opin. Invest. Drugs, 2: 617-626, 1993.
11. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P., and Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov. Today, 1: 16-26, 1996.
12. Talbot, D. C., and Brown, P. D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer, 32A: 2528-2533, 1996.
13. Rasmussen, H. S., and McCann, P. P. Matrix metalloproteinase inhibitors as a novel anticancer strategy: a review with special focus on Batimastat and Marimastat. Pharmacol. Ther., 75: 69-75, 1997.
14. White, A. D., Bocan, T. M. A., Boxer, P. A., Peterson, J. T., and Dchrier, D. Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. Curr. Pharm. Des., 3: 45-58, 1997
15. Coleman, S. G. Matrix metalloproteinase inhibitors. Drugs R D, 1: 131-134, 1999.
16. Sugita, K. Recent advance in inhibitors of matrix metalloproteinases for cancer therapy. IDrugs, 2: 327-339, 1999.
17. Denis, L. J., and Verweij, J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Investig. New Drugs, 15: 175-185, 1997.
18. Galis, Z. S., Sukhova, G. K., and Libby, P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J., 9: 974-980, 1995.
19. Knox, J. B., Sukhova, G. K., Whittemore, A. D., and Libby, P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic disease. Circulation, 95: 205-212, 1997.
20. Mungall, B. A., Pollitt, C. C., and Collins, R. Localization of gelatinase activity in epidermal hoof lamellae by in situ zymography. Histochem. Cell Biol., 110: 535-540, 1998.
21. Krejci-Papa, N. C., and Paus, R. A novel in-situ-zymography technique localizes gelatinolytic activity in human skin to mast cells. Exp. Dermatol., 7: 321-326, 1998.
22. Nakamura, H., Ueno, H., Yamashita, K., Shimada, T., Yamamoto, E., Noguchi, M., Fujimoto, N., Sato, H., Seiki, M., and Okada, Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res., 59: 467-473, 1999.
23. Tamura, Y., Watanabe, H., Nakatani, T., Yasui, K., Fuji, M., Komurasaki, T., Tsuzuki, H., Maekawa, R., Yoshioka, T., Kawada, K., Sugita, K., and Ohtani, M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem., 41: 640-649, 1998.
24. Maekawa, R., Maki, H., Yoshida, H., Hojo, K., Tanaka, H., Wada, T., Uchida, N., Takeda, Y., Kasai, H., Okamoto, H., Tsuzuki, H., Kambayashi, Y., Watanabe, F., Kawada, K., Toda, K, Ohtani, M., Sugita, K., and Yoshioka, T. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonylphenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res., 59: 1231-1235, 1999.
25. Tanaka, H., Hojo, K., Yoshida, H., Yoshioka, T., and Sugita, K. Molecular cloning and expression of the mouse 105-kDa gelatinase cDNA. Biochem. Biophys. Res. Commun., 190: 732-740, 1993.